Teknova’s Q1 2026: Revenue Rises, Guidance Holds, and the Missing EPS Moment

Quarterly results at a glance

Teknova, Inc. (Nasdaq: TKNO) reported first-quarter 2026 revenue of $11.1 million, up 13% from $9.8 million in the same quarter a year earlier. Notably, the release focuses on top-line growth and liquidity rather than an earnings-per-share figure, leaving EPS and earnings surprise discussions to later scrutiny. The company reaffirmed its revenue forecast for 2026 of $42–$44 million and continues to anticipate full-year free cash outflow of less than $10 million.

Key financials and guidance

• First-quarter 2026 revenue: $11.1 million; Q1 2025 revenue: $9.8 million.
• Cash and short-term investments: $17.8 million; total borrowings: $13.2 million at quarter end.
• Revenue guidance for 2026: $42–$44 million; expected full-year free cash outflow: < $10 million.

Management’s framing emphasizes resilience in demand for Teknova’s core reagent offerings and the company’s capital posture as it navigates a growth phase that is more about scale and efficiency than a one-quarter sprint.

Management commentary

“We had a great start to 2026,” said Stephen Gunstream, Teknova’s President and Chief Executive Officer. “The substantial investments we’ve made since 2021, combined with an improved market backdrop, position Teknova for sustainable above-market growth over the next couple years, particularly as our Clinical Solutions customers advance their therapies and diagnostics toward commercialization.”

Chief Financial Officer Matt Lowell added: “We delivered strong financial results in the first quarter 2026 compared to 2025, including 13% revenue growth and significant improvements in Adjusted EBITDA and Free Cash Outflow. We therefore reiterate our 2026 revenue guidance of $42–$44 million and continue to anticipate full-year Free Cash Outflow of less than $10 million.”

What this portends for Teknova and sector peers

Teknova’s narrative centers on durability and cash discipline in a market for critical reagents used in discovery, development, and diagnostics. The Q1 results suggest the company can deliver year-over-year growth while keeping cash burn in check—a combination peers will watch closely as they manage R&D intensity against manufacturing scale. With the revenue forecast intact, investors will assess whether Teknova’s pathway to “above-market growth” remains anchored in its long-cycle clinical solutions clientele and the efficiency gains implied by the cash outflow target.

Earnings metrics, EPS, and the industry lens

The release foregrounds revenue and cash flow rather than an EPS figure. As a result, there is no disclosed EPS, nor explicit EPS consensus or earnings surprise data in this filing. In the small-cap biotech-tools space, that focus on top-line stability and cash runway can be as decisive as a quarterly beat on EPS elsewhere. If and when Teknova surfaces an EPS figure, it would likely hinge on margin progression and operating leverage as the company scales, especially in the back half of 2026.

Revenue forecast and the longer arc

Teknova’s reaffirmed 2026 revenue forecast of $42–$44 million signals management’s confidence in sustained demand for its reagents and services. For market participants, that range helps anchor expectations for EPS trajectories once margins and one-time items are clarified. The narrative thus far favors a gradual improvement in profitability and cash efficiency, rather than a sudden margin explosion.

Bottom line

Teknova’s Q1 2026 results deliver a clean narrative: revenue growth, a steady cash position, and a reaffirmed 2026 revenue target. The absence of an EPS figure and related surprises narrows near-term catalysts to top-line momentum and cash management, while the company’s investment cadence and customer trajectory suggest why analysts and peers will monitor Teknova as a proxy for sector health in 2026.